Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT)

Clinica Chimica Acta

Volumn 411, Issue 7-8, 2010, Pages 494-499

  Ojeda Fernandez, Luisa ^a   Barrios, Laura ^b   Rodriguez Barbero, Alicia ^c   Recio Poveda, Lucia ^a   Bernabeu, Carmelo ^a   Botella, Luisa M ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b CSIC Centro Tecnico de Informatica CTI   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

ALK1; Angiopoietin 2; Endoglin; Hereditary haemorrhagic telangiectasia; Rare disease; Soluble endoglin

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ANGIOPOIETIN 2; BIOLOGICAL MARKER; ENDOGLIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADULT; AGED; ALGORITHM; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HEREDITARY HEMORRHAGIC TELANGIECTASIA 1; HEREDITARY HEMORRHAGIC TELANGIECTASIA 2; HEREDITARY HEMORRHAGIC TELANGIECTASIA 3; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RENDU OSLER WEBER DISEASE; SIGNAL TRANSDUCTION;

EID: 77649192800     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.12.023     Document Type: Article

References (36)

1. Guttmacher A.E., Marchuk D.A., White R.I. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995, 333:918-924.
2. Haitjema T., Westermann C.J., Overtoom T.T., et al. Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): new insights in pathogenesis, complications, and treatment. Arch Intern Med 1996, 156:714-719.
3. Kjeldsen A.D., Vase P., Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 1999, 245:31-39.
4. Plauchu H., de Chadarevian J.-P., Bideau A., et al. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989, 32:291-297.
5. Govani F.S., Shovlin C.L. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009, 7:860-871. Review.
6. Fernandez-Ruiz E., St-Jacques S., Bellón T., Letarte M., Bernabeu C. Assignment of the human endoglin gene (END) to 9q34qter. Cytogenet Cell Genet 1993, 64:204-207.
7. McAllister K.A., Grogg K.M., Johnson D.W., et al. Endoglin, a TGF- binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994, 8:345-351.
8. Johnson D.W., Berg J.N., Gallione C.J., et al. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 1995, 5:21-28.
9. Johnson D.W., Berg J.N., Baldwin M.A., et al. Mutations in the activin receptor-like kinase 1 gene in hereditary hemorrhagic telangiectasia type 2. Nat Genet 1996, 13:189-195.
10. Cole S.G., Begbie M.E., Wallace G.M., Shovlin C.L. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005, 42:577-582.
11. Bayrak-Toydemir P., McDonald J., Akarsu N., et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 2006, 140:2155-2162.
12. Gallione C.J., Repetto G.M., Legius E., et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004, 363:852-859.
13. Shovlin C.L., Guttmacher A.E., Buscarini E., et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000, 91:66-67.
14. Faughnan M.E., Palda V.A., Garcia-Tsao G., Geisthoff U.W., McDonald J., Proctor D.D., Spears J., Brown D.H., Buscarini E., Chesnutt M.S. International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. J Med Genet Jun 29 2009, Electronic publication ahead of print.
15. Fernandez-L A., Garrido-Martin E.M., Sanz-Rodriguez F., et al. Gene expression fingerprinting for human hereditary hemorrhagic telangiectasia. Hum Mol Genetic 2007, 16:1515-1533.
16. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
17. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
18. Gale N.W., Thurston G., Hackett S.F., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002, 3:411-423.
19. Lemieux C., Maliba R., Favier J., Théorêt J.F., Merhi Y., Sirois M.G. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood 2005, 105:1523-1530.
20. Tanaka S., Mori M., Sakamoto Y., Makuuchi M., Sugimachi K., Wands J.R. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999, 103:341-345.
21. Scholz A., Rehm V.A., Rieke S., et al. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 2007, 102:2471-2478.
22. Schliemann C., Bieker R., Thoennissen N., et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 2007, 21:1901-1906.
23. Siner J.M., Bhandari V., Engle K.M., Elias J.A., Siegel M.D. Elevated serum angiopoietin 2 levels are associated with increased mortality in sepsis. Shock 2009, 31:348-353.
24. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12:642-649.
25. Cruz-Gonzalez I., Pabón P., Rodríguez-Barbero A., et al. Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction. J Cell Mol Med 2008, 12:955-961.
26. Li C., Guo B., Wilson P.B., et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 2000, 89:122-126.
27. Takahashi N., Kawanishi-Tabata R., Haba A., et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 2001, 7:524-532.
28. Li D.Y., Sorensen L.K., Brooke B.S., et al. Defective angiogenesis in mice lacking endoglin. Science 1999, 284:1534-1537.
29. Bourdeau A., Dumont D.J., Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999, 104:1343-1351.
30. Arthur H.M., Ure J., Smith A.J., et al. Endoglin, an ancillary TGFβ receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000, 217:42-53.
31. Jerkic M., Rodríguez-Barbero A., Prieto M., et al. Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc Res 2006, 69:845-854.
32. Bernabeu C., Conley B.A., Vary C.P. Novel biochemical pathways of endoglin in vascular cell physiology. J Cell Biochem 2007, 102:1375-1388.
33. Fernandez-L A., Sanz-Rodriguez F., Zarrabeitia R., et al. Blood outgrowth endothelial cells from hereditary haemorrhagic telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res 2005, 68:235-248.
34. Fernandez-L A., Sanz-Rodriguez F., Zarrabeitia R., et al. Mutation study of Spanish patients with hereditary haemorrhagic telangiectasia. Expression analysis of endoglin and ALK1. Hum Mut 2006, 27:295.
35. Sanz-Rodriguez F., Fernandez-L A., Zarrabeitia R., et al. Deficient endoglin upregulation in activated monocytes from hereditary hemorrhagic telangiectasia patients. Clin Chem 2004, 50:2003-2011.
36. Afifi A.A., Clark V. Discriminant analysis. Computer-aided multivariate analysis 1996, 243-280. Belmont, California. Chapman & Hall/CRC (Ed.).